BRIEF

on Xenetic Biosciences, Inc. (NASDAQ:XBIO)

Xenetic Biosciences Extends Partnership with Scripps to Boost DNase Oncology Program

Stock price chart of Xenetic Biosciences, Inc. (EBR:XBIO) showing fluctuations.

Xenetic Biosciences, Inc. has announced an extension of its collaboration with The Scripps Research Institute to advance its DNase oncology platform. The company's DNase I candidate is under preclinical evaluation combined with CAR T-cell therapies, targeting hematological cancers and metastatic melanoma. Prior studies have indicated that DNase I enhances CAR T-cell therapy by reducing tumor burden and enhancing immune response.

This initiative focuses on degrading neutrophil extracellular traps (NETs), structures that contribute to cancer spread. Xenetic aims to incorporate DNase I as an adjunctive treatment to improve therapeutic responses in CAR T-cell therapies. The collaboration with Scripps also offers Xenetic the option to acquire licenses for new intellectual property emerging from the DNase research.

The company's strategy is oriented towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other tumors. The extension of the research agreement signifies Xenetic's commitment to leveraging cutting-edge science to enhance cancer treatment.

R. E.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Xenetic Biosciences, Inc. news